O	0	16	Cardioprotective
O	17	24	Effects
O	25	27	of
B-intervention	28	38	Carvedilol
O	39	41	in
O	42	52	Inhibiting
O	53	64	Doxorubicin
O	64	65	-
O	65	72	induced
O	73	87	Cardiotoxicity
O	87	88	.

O	89	103	Anthracyclines
O	104	105	(
O	105	109	ANTs
O	109	110	)
O	111	114	are
O	115	116	a
O	117	122	class
O	123	125	of
O	126	132	active
O	133	147	antineoplastic
O	148	154	agents
O	155	159	with
O	160	173	topoisomerase
O	173	174	-
O	174	185	interacting
O	186	194	activity
O	195	199	that
O	200	203	are
O	204	214	considered
O	215	218	the
O	219	223	most
O	224	230	active
O	231	237	agents
O	238	241	for
O	242	245	the
O	246	255	treatment
O	256	258	of
O	259	265	breast
O	266	272	cancer
O	272	273	.

O	274	276	We
O	277	289	investigated
O	290	293	the
O	294	302	efficacy
O	303	305	of
O	306	316	carvedilol
O	317	319	in
O	320	323	the
O	324	334	inhibition
O	335	337	of
O	338	341	ANT
O	341	342	-
O	342	349	induced
O	350	364	cardiotoxicity
O	364	365	.

O	366	368	In
O	369	373	this
O	374	384	randomized
O	384	385	,
O	386	392	single
O	392	393	-
O	393	398	blind
O	398	399	,
O	400	407	placebo
O	407	408	-
O	408	418	controlled
O	419	424	study
O	424	425	,
B-total-participants	426	428	91
O	429	434	women
O	435	439	with
O	440	448	recently
O	449	458	diagnosed
O	459	465	breast
O	466	472	cancer
O	473	483	undergoing
O	484	487	ANT
O	488	495	therapy
O	496	500	were
O	501	509	randomly
O	510	518	assigned
O	519	521	to
O	522	528	groups
O	529	536	treated
O	537	541	with
O	542	548	either
O	549	559	carvedilol
O	560	561	(
O	561	562	n
O	563	564	=
B-intervention-participants	565	567	46
O	567	568	)
O	569	571	or
B-control	572	579	placebo
O	580	581	(
O	581	582	n
O	583	584	=
B-control-participants	585	587	45
O	587	588	)
O	588	589	.

O	590	606	Echocardiography
O	607	610	was
O	611	620	performed
O	621	627	before
O	628	631	and
O	632	634	at
O	635	636	6
O	637	643	months
O	644	649	after
O	650	663	randomization
O	663	664	,
O	665	668	and
O	669	677	absolute
O	678	685	changes
O	686	688	in
O	689	692	the
O	693	697	mean
O	698	702	left
O	703	714	ventricular
O	715	723	ejection
O	724	732	fraction
O	732	733	,
O	734	738	left
O	739	750	ventricular
O	751	754	end
O	755	764	diastolic
O	765	771	volume
O	771	772	,
O	773	776	and
O	777	781	left
O	782	793	ventricular
O	794	797	end
O	798	806	systolic
O	807	813	volume
O	814	818	were
O	819	829	determined
O	829	830	.

O	831	842	Furthermore
O	842	843	,
O	844	847	the
O	848	858	percentage
O	859	865	change
O	866	868	in
O	869	872	the
O	873	877	left
O	878	884	atrial
O	885	886	(
O	886	888	LA
O	888	889	)
O	890	898	diameter
O	899	902	and
O	903	908	other
O	909	918	variables
O	919	921	of
O	922	926	left
O	927	938	ventricular
O	939	940	(
O	940	942	LV
O	942	943	)
O	944	953	diastolic
O	954	962	function
O	962	963	,
O	964	968	such
O	969	971	as
O	972	983	transmitral
O	984	991	Doppler
O	992	1002	parameters
O	1002	1003	,
O	1004	1013	including
O	1014	1019	early
O	1020	1021	(
O	1021	1022	E
O	1023	1027	wave
O	1027	1028	)
O	1029	1032	and
O	1033	1037	late
O	1038	1039	(
O	1039	1040	A
O	1041	1045	wave
O	1045	1046	)
O	1047	1056	diastolic
O	1057	1067	velocities
O	1067	1068	,
O	1069	1070	E
O	1070	1071	/
O	1071	1072	A
O	1073	1078	ratio
O	1079	1082	and
O	1083	1084	E
O	1085	1089	wave
O	1090	1102	deceleration
O	1103	1107	time
O	1107	1108	,
O	1109	1118	pulmonary
O	1119	1125	venous
O	1126	1133	Doppler
O	1134	1141	signals
O	1141	1142	,
O	1143	1152	including
O	1153	1160	forward
O	1161	1169	systolic
O	1170	1171	(
O	1171	1172	S
O	1173	1177	wave
O	1177	1178	)
O	1179	1182	and
O	1183	1192	diastolic
O	1193	1194	(
O	1194	1195	D
O	1196	1200	wave
O	1200	1201	)
O	1202	1212	velocities
O	1213	1217	into
O	1218	1220	LA
O	1220	1221	,
O	1222	1226	late
O	1227	1236	diastolic
O	1237	1243	atrial
O	1244	1252	reversal
O	1253	1261	velocity
O	1261	1262	,
O	1263	1266	and
O	1267	1272	early
O	1273	1282	diastolic
O	1283	1289	tissue
O	1290	1297	Doppler
O	1298	1304	mitral
O	1305	1312	annular
O	1313	1321	velocity
O	1322	1323	(
O	1323	1324	e
O	1324	1325	'
O	1325	1326	)
O	1327	1331	were
O	1332	1340	measured
O	1340	1341	.

O	1342	1344	In
O	1345	1353	addition
O	1353	1354	,
O	1355	1361	tissue
O	1362	1369	Doppler
O	1370	1376	mitral
O	1377	1384	annular
O	1385	1393	systolic
O	1394	1395	(
O	1395	1396	s
O	1396	1397	'
O	1397	1398	)
O	1399	1407	velocity
O	1407	1408	,
O	1409	1411	as
O	1412	1413	a
O	1414	1420	marker
O	1421	1423	of
O	1424	1429	early
O	1430	1435	stage
O	1436	1438	of
O	1439	1441	LV
O	1442	1450	systolic
O	1451	1462	dysfunction
O	1462	1463	,
O	1464	1465	E
O	1465	1466	/
O	1466	1467	e
O	1467	1468	'
O	1469	1474	ratio
O	1474	1475	,
O	1476	1478	as
O	1479	1480	a
O	1481	1492	determinant
O	1493	1495	of
O	1496	1498	LV
O	1499	1506	filling
O	1507	1515	pressure
O	1515	1516	,
O	1517	1520	and
O	1521	1529	troponin
O	1530	1531	I
O	1532	1537	level
O	1537	1538	,
O	1539	1541	as
O	1542	1543	a
O	1544	1550	marker
O	1551	1553	of
O	1554	1564	myocardial
O	1565	1573	necrosis
O	1574	1578	were
O	1579	1587	measured
O	1587	1588	.

O	1589	1591	At
O	1592	1595	the
O	1596	1599	end
O	1600	1602	of
O	1603	1609	follow
O	1609	1610	-
O	1610	1612	up
O	1613	1619	period
O	1619	1620	,
B-outcome	1621	1625	left
I-outcome	1626	1637	ventricular
I-outcome	1638	1646	ejection
I-outcome	1647	1655	fraction
O	1656	1659	did
O	1660	1663	not
O	1664	1670	change
O	1671	1673	in
O	1674	1677	the
O	1678	1688	carvedilol
O	1689	1694	group
O	1694	1695	.

O	1696	1703	However
O	1703	1704	,
O	1705	1709	this
O	1710	1719	parameter
O	1720	1723	was
O	1724	1737	significantly
O	1738	1745	reduced
O	1746	1748	in
O	1749	1752	the
O	1753	1760	control
O	1761	1766	group
O	1767	1768	(
O	1768	1769	P
O	1770	1771	<
O	1772	1773	0
O	1773	1774	.
O	1774	1777	001
O	1777	1778	)
O	1778	1779	.

O	1780	1796	Echocardiography
O	1797	1803	showed
O	1804	1808	that
O	1809	1813	both
B-outcome	1814	1818	left
I-outcome	1819	1830	ventricular
I-outcome	1831	1834	end
I-outcome	1835	1843	systolic
I-outcome	1844	1850	volume
I-outcome	1851	1854	and
I-outcome	1855	1857	LA
I-outcome	1858	1866	diameter
O	1867	1871	were
O	1872	1885	significantly
O	1886	1895	increased
O	1896	1904	compared
O	1905	1909	with
O	1910	1913	the
O	1914	1922	baseline
O	1923	1931	measures
O	1932	1934	in
O	1935	1938	the
O	1939	1946	control
O	1947	1952	group
O	1952	1953	.

O	1954	1956	In
O	1957	1962	pulse
O	1963	1970	Doppler
O	1971	1978	studies
O	1978	1979	,
B-outcome	1980	1989	pulmonary
I-outcome	1990	1996	venous
I-outcome	1997	2001	peak
I-outcome	2002	2008	atrial
I-outcome	2009	2017	reversal
I-outcome	2018	2022	flow
I-outcome	2023	2031	velocity
O	2032	2035	was
O	2036	2049	significantly
O	2050	2059	increased
O	2060	2062	in
O	2063	2066	the
O	2067	2074	control
O	2075	2080	group
O	2080	2081	.

O	2082	2090	Moreover
O	2090	2091	,
O	2092	2093	a
O	2094	2105	significant
O	2106	2114	decrease
O	2115	2117	in
O	2118	2121	the
B-outcome	2122	2128	mitral
I-outcome	2129	2135	annuli
I-outcome	2136	2141	early
I-outcome	2142	2151	diastolic
I-outcome	2152	2153	(
I-outcome	2153	2154	e
I-outcome	2154	2155	'
I-outcome	2155	2156	)
I-outcome	2157	2160	and
I-outcome	2161	2165	peak
I-outcome	2166	2174	systolic
I-outcome	2175	2176	(
I-outcome	2176	2177	s
I-outcome	2177	2178	'
I-outcome	2178	2179	)
I-outcome	2180	2190	velocities
O	2191	2194	and
O	2195	2196	a
O	2197	2208	significant
O	2209	2217	increase
O	2218	2220	in
O	2221	2224	the
B-outcome	2225	2226	E
I-outcome	2227	2228	(
I-outcome	2228	2231	the
I-outcome	2232	2236	peak
I-outcome	2237	2242	early
I-outcome	2243	2252	diastolic
I-outcome	2253	2261	velocity
I-outcome	2261	2262	)
I-outcome	2262	2263	/
I-outcome	2263	2264	e
I-outcome	2264	2265	'
I-outcome	2266	2271	ratio
O	2272	2274	in
O	2275	2278	the
O	2279	2286	control
O	2287	2292	group
O	2293	2297	were
O	2298	2302	also
O	2303	2311	observed
O	2311	2312	.

O	2313	2320	However
O	2320	2321	,
O	2322	2326	none
O	2327	2329	of
O	2330	2335	these
O	2336	2345	variables
O	2346	2350	were
O	2351	2360	adversely
O	2361	2368	changed
O	2369	2371	at
O	2372	2375	the
O	2376	2379	end
O	2380	2382	of
O	2383	2389	follow
O	2389	2390	-
O	2390	2392	up
O	2393	2395	in
O	2396	2399	the
O	2400	2410	carvedilol
O	2411	2416	group
O	2416	2417	.

O	2418	2429	Furthermore
O	2429	2430	,
O	2431	2434	the
B-outcome	2435	2438	TnI
I-outcome	2439	2444	level
O	2445	2448	was
O	2449	2462	significantly
O	2463	2469	higher
O	2470	2472	in
O	2473	2476	the
O	2477	2484	control
O	2485	2490	group
O	2491	2495	than
O	2496	2498	in
O	2499	2502	the
O	2503	2513	carvedilol
O	2514	2519	group
O	2520	2521	(
O	2521	2522	P
O	2523	2524	=
O	2525	2526	0
O	2526	2527	.
O	2527	2530	036
O	2530	2531	)
O	2532	2534	at
O	2535	2537	30
O	2538	2542	days
O	2543	2548	after
O	2549	2552	the
O	2553	2563	initiation
O	2564	2566	of
O	2567	2579	chemotherapy
O	2579	2580	.

O	2581	2593	Prophylactic
O	2594	2597	use
O	2598	2600	of
O	2601	2611	carvedilol
O	2612	2615	may
O	2616	2623	inhibit
O	2624	2627	the
O	2628	2639	development
O	2640	2642	of
O	2643	2656	anthracycline
O	2656	2657	-
O	2657	2664	induced
O	2665	2679	cardiotoxicity
O	2679	2680	,
O	2681	2685	even
O	2686	2688	at
O	2689	2692	low
O	2693	2698	doses
O	2698	2699	.
